Jinying Xia

Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta‐analysis

Jun Xu, Danzhen Yao, Jinying Xia, 2021, Journal of clinical pharmacy and therapeutics.

Nomogram for Quantitatively Estimating the Risk of Fibrosis Progression in Type 2 Diabetic Patients With Nonalcoholic Fatty Liver Disease: A Pilot Study

S. Cui, Jinying Xia, Qi-qi Hua, 2022, Frontiers in Endocrinology.

Development of a Nomogram for Estimating the Risk of Left Ventricular Diastolic Dysfunction in Patients with Non-Alcoholic Fatty Liver Disease

Danzhen Yao, Jinying Xia, Qi-qi Hua, 2022, Diabetes, metabolic syndrome and obesity : targets and therapy.

Association of serum chemerin and inflammatory factors with type 2 diabetes macroangiopathy and waist-to-stature ratio.

Jie Xu, Jie Yu, Mengxue Yang, 2019, Bosnian journal of basic medical sciences.

Data-driven classification of prediabetes using cardiometabolic biomarkers: Data from National Health and Nutrition Examination Survey 2007–2016

Jinying Xia, Yan Jiang, Caiyan Che, 2022, Frontiers in Endocrinology.

Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse

Danzhen Yao, Jinying Xia, Jianhui Li, 2018, International journal of endocrinology.

Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo.

Guosheng Gao, Jingjing Ying, Jinying Xia, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

MiR-346 and TRAb as Predicative Factors for Relapse in Graves’ Disease Within One Year

Danzhen Yao, Jinying Xia, Yawei Cai, 2017, Hormone and Metabolic Research.